The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
85
AdventHealth Orlando
Orlando, Florida, United States
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Columbia University Irving Medical Center
New York, New York, United States
Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined)
Time frame: Baseline up to Week 17 (inclusive)
Change from Baseline in Sleep Metabolic Rate (SMR)
In participants who achieve target weight loss
Time frame: Baseline up to Week 16 (inclusive)
Change from Baseline in SMR
Time frame: Baseline up to Week 16 (inclusive)
Change from Baseline in 24-hour Energy Expenditure (EE)
In participants who achieve target weight loss
Time frame: Baseline up to Week 16 (inclusive)
Change from Baseline in 24-hour EE
Time frame: Baseline up to Week 16 (inclusive)
Change from Baseline in Total Calorie Intake at Lunch
Time frame: Baseline up to Week 17 (inclusive)
Change from Baseline in Total Calorie Intake at Dinner
Time frame: Baseline up to Week 17 (inclusive)
Change from Baseline in Fasting Appetite Visual Analog Score (VAS)
Time frame: Baseline up to Week 16 (inclusive)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.